Riverbridge Partners LLC Sells 5,734 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Riverbridge Partners trimmed its position in IDEXX by 6.0%, selling 5,734 shares and leaving 89,699 shares valued at about $60.68 million, making IDEXX its 27th largest holding (≈1.1% of Riverbridge's portfolio).
• Several brokerages have cut price targets recently, but the stock retains a consensus rating of Moderate Buy with an average target of $783.33.
• IDEXX beat Q4 estimates with EPS of $3.08 (vs. $2.93 expected) and revenue up 14.3% year-over-year, while issuing FY2026 guidance of $14.29–$14.80 in EPS.

Riverbridge Partners LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 89,699 shares of the company's stock after selling 5,734 shares during the quarter. IDEXX Laboratories makes up approximately 1.1% of Riverbridge Partners LLC's holdings, making the stock its 27th largest holding. Riverbridge Partners LLC owned about 0.11% of IDEXX Laboratories worth $60,684,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of IDXX. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at $29,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the third quarter valued at about $31,000. Finally, Armstrong Advisory Group Inc. boosted its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on IDXX. Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. UBS Group lowered their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research report on Tuesday, February 3rd. BTIG Research dropped their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Finally, Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $783.33.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899 shares of the company's stock, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock worth $29,862,109 over the last ninety days. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Down 0.4%

NASDAQ:IDXX opened at $573.29 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The business's 50-day moving average price is $634.46 and its two-hundred day moving average price is $662.53. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $45.59 billion, a price-to-earnings ratio of 43.86, a PEG ratio of 3.50 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.